From my understanding, $3.95 AUD per share is evaluated after taking all risks.
Based on the report's valuation, calculation for if the product is successful can be derived as follow.
if GVHD (ex-Japan) is successful (US + other countries- equally weighted), it adds (0.28/0.7-0.28)*1.4 = 0.168 AUD, to the valuation.
if Revascor LVAD is successful, it adds (0.06/0.33-0.06)*1.4 = 0.17 AUD
if Chronic backpain is successful, it adds (0.75/0.44-0.75)*1.4= 1.33 AUD
if Revascor (CHF) is successful, it adds (2/0.6-2)*1.4=1.86 AUD
But, I think every valuation has too many assumptions, so it's not very useful.
It's probably easier to think in term of probability of regulatory approval and how many life they will improve.
As long as the approved product will improve life significantly and be reasonably accessible by patients, MSB's value should be worth a bit.
- Forums
- ASX - By Stock
- Bell Potter report - 28-Feb
From my understanding, $3.95 AUD per share is evaluated after...
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.01 |
Change
0.010(1.01%) |
Mkt cap ! $1.147B |
Open | High | Low | Value | Volume |
99.0¢ | $1.03 | 98.5¢ | $1.122M | 1.121M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 3253 | $1.01 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.01 | 20571 | 7 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
16 | 37810 | 0.995 |
14 | 139433 | 0.990 |
9 | 43881 | 0.985 |
8 | 55136 | 0.980 |
5 | 23615 | 0.975 |
Price($) | Vol. | No. |
---|---|---|
1.000 | 42232 | 16 |
1.005 | 55543 | 10 |
1.010 | 39514 | 11 |
1.015 | 21975 | 5 |
1.020 | 51224 | 2 |
Last trade - 11.28am 05/09/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |